Review Article
Combination of Immune Checkpoint Inhibitors and Radiotherapy for Advanced Non-Small-Cell Lung Cancer and Prostate Cancer: A Meta-Analysis
Table 1
Characteristics of the 3 studies included in the meta-analysis.
| | Study | RCT phase | Pathology | Line | Age | Male (%) | Treatment comparison | Case | ICI | RT site | Follow-up of ICI + RT
(months) | HR (95% CI) for ICI + RT | | OS | PFS |
| | Antonia et al. [12] | 3 | NSCLC | 1 | <65 y 387 ≥ 65 y 322 | 70.1 | Receive chemoradiotherapy followed by durvalumab vs. placebo | 473 vs. 236 | Dur:10 mg/kg Q2W | Lung | 14.5 | 0.68
(0.47–0.997) | 0.51
(0.41–0.63) |
| | Kwon et al. [10] | 3 | Prostate cancer | 2 | <70 y 449 ≥ 70 y 350 | 100 | Receive RT followed by ipilimumab vs. placebo | 399 vs. 400 | Ipi:10 mg/kg Q3W | Bone | 9.9 | 0.85
(0.72–1.00) | 0.70
(0.61–0.82) |
| | Theelen et al. [11] | 2 | NSCLC | 1, 2 | <65 y 31 ≥ 65 y 28 | 57.6 | Pembrolizumab after radiotherapy vs. pembrolizumab alone | 36 vs. 40 | Pem:200 mg/kg Q3W | Lung | 23.6 | 0.66
(0.37–1.18) | 0.71
(0.42–1.18) |
|
|
Notes: Dur: durvalumab; Ipi: Ipilimumab; Pem: pembrolizumab. HR: hazard ratio; ICI: Immune checkpoint inhibitors; NSCLC: nonsmall-cell lung cancer; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; Q2W: every 2 weeks; Q3W: every 3 weeks; RCT: randomized controlled trials; RT: radiotherapy; y: years.
|
